Added to YB: 2024-03-21
Pitch date: 2023-12-31
ARGX [bullish]
argenx SE
+121.53%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 340.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Show full summary:
ClearBridge Investments Mid Cap Strategy Added On Portfolio Holding: argenx SE
ARGX: Added to position on dip despite lackluster Ph3 data due to trial design. Optimistic long-term given strong balance sheet & potential to treat dozens of autoimmune conditions with platform. Like biotech's prospects.
Read full article (1 min)